LLY News and Press, Eli Lilly and Company From 01/12/24

2024-01-12 13:46:01 ET Summary Pfizer Inc. stock has been on a protracted, yearlong decline due to stronger-than-expected normalization in COVID product uptake rates in 2023. But management's conservative 2024 guidance for COVID product revenues sufficiently de-risks for related h...

2024-01-12 11:55:01 ET Summary GLP-1 weight-loss drugs are impacting the pharmaceutical industry and external industries like apparel. Lululemon is expected to benefit from the demand for new clothes as people lose weight. The growing popularity of weight-loss drugs, particula...

2024-01-12 00:25:11 ET Summary Novo Nordisk is the market leader of the fast-growing obesity care industry, which is expected to grow above 20% CAGR until 2030. The company raised three times its guidance during 2023, driven by a 481% growth in Wegovy's revenues. The company i...

2024-01-11 11:56:59 ET Popular weight loss drugs from Novo Nordisk ( NVO ) and Eli Lilly ( NYSE: LLY ) do not cause suicidal thoughts or actions, according to a preliminary evaluation from the U.S. FDA. The drugs, such as Novo's ( NVO ) Wegovy (semaglutide) and Lill...

2024-01-11 09:56:01 ET More on Lantheus Lantheus Stock: Looking To Add After SPLASH's Belly-Flop Lantheus: SPLASHdown, Navigating Waves In MCRPC Treatment Lantheus Holdings: Huge Catalysts Ahead And Cheap Valuation Lantheus says FY23 worldwide revenue is expe...

2024-01-11 05:49:00 ET Shares of Eli Lilly and Company (NYSE: LLY) skyrocketed 59% in 2023. The big drugmaker delivered its second-best stock performance in the last 25 years, eclipsed only by a gain of nearly 64% in 2021. Lilly's spectacular jump also enabled the company to cla...

2024-01-11 04:46:33 ET Summary Eli Lilly's weight-loss drug Zepbound, with increasing demand and expected insurance coverage, indicates a significant growth opportunity. Continued success in GLP-1 therapies positions LLY as a leader in the obesity management market, poised for pro...

Partnership expands Henlius’ portfolio with license of exclusive China rights to develop, manufacture and commercialize lasofoxifene; Sermonix retains all other global rights Henlius to facilitate clinical development for the initiated Phase 3 MRCT (ELAINE-3) of lasofoxifene in the...

2024-01-10 18:02:30 ET More on Novo Nordisk Novo Nordisk A/S (NVO) Presents at J.P. Morgan 42nd Annual Healthcare Conference Transcript Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportuni...

2024-01-10 12:09:02 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript) Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) Regeneron Pharmaceuticals Inc. (REGN) Am...